1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Growth Disorders - Pipeline Review, H2 2013

Growth Disorders - Pipeline Review, H2 2013

  • August 2013
  • -
  • Global Markets Direct
  • -
  • 67 pages

Growth Disorders - Pipeline Review, H2 2013

Summary

Global Markets Direct’s, 'Growth Disorders - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Growth Disorders, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Growth Disorders. Growth Disorders - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Growth Disorders.
- A review of the Growth Disorders products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Growth Disorders pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Growth Disorders.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Growth Disorders pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table Of Contents

Growth Disorders - Pipeline Review, H2 2013
Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Growth Disorders Overview 8
Therapeutics Development 9
An Overview of Pipeline Products for Growth Disorders 9
Growth Disorders Therapeutics under Development by Companies 11
Growth Disorders Therapeutics under Investigation by Universities/Institutes 13
Late Stage Products 14
Comparative Analysis 14
Mid Clinical Stage Products 15
Comparative Analysis 15
Early Clinical Stage Products 16
Comparative Analysis 16
Discovery and Pre-Clinical Stage Products 17
Comparative Analysis 17
Growth Disorders Therapeutics - Products under Development by Companies 18
Growth Disorders Therapeutics - Products under Investigation by Universities/Institutes 19
Companies Involved in Growth Disorders Therapeutics Development 20
Novo Nordisk A/S 20
Ipsen S.A. 21
Dong-A Pharmaceutical Co., Ltd. 22
Zosano Pharma, Inc. 23
PROLOR Biotech, Inc. 24
Biovitrum AB 25
JCR Pharmaceuticals Co., Ltd. 26
Myungmoon pharmaceutical Co.,Ltd. 27
Asterion Ltd 28
GeneScience Pharmaceuticals Co., Ltd. 29
Phage Biotechnology Corporation 30
USV Limited. 31
Growth Disorders - Therapeutics Assessment 32
Assessment by Monotherapy Products 32
Assessment by Route of Administration 33
Assessment by Molecule Type 35
Drug Profiles 37
MOD-4023 - Drug Profile 37
Product Description 37
Mechanism of Action 37
RandD Progress 37
somatropin - Drug Profile 39
Product Description 39
Mechanism of Action 39
RandD Progress 39
somatropin - Drug Profile 40
Product Description 40
Mechanism of Action 40
RandD Progress 40
bucelipase alfa - Drug Profile 42
Product Description 42
Mechanism of Action 42
RandD Progress 42
somatropin biosimilar - Drug Profile 44
Product Description 44
Mechanism of Action 44
RandD Progress 44
somatropin Long-Acting - Drug Profile 45
Product Description 45
Mechanism of Action 45
RandD Progress 45
somatropin - Drug Profile 46
Product Description 46
Mechanism of Action 46
RandD Progress 46
Pegylated somatropin - Drug Profile 47
Product Description 47
Mechanism of Action 47
RandD Progress 47
Human Growth Hormone ZP Patch - Drug Profile 48
Product Description 48
Mechanism of Action 48
RandD Progress 48
xl-020 - Drug Profile 49
Product Description 49
Mechanism of Action 49
RandD Progress 49
Growth Hormone Agonists - Drug Profile 50
Product Description 50
Mechanism of Action 50
RandD Progress 50
somatropin - Drug Profile 51
Product Description 51
Mechanism of Action 51
RandD Progress 51
MM-P02-01 - Drug Profile 52
Product Description 52
Mechanism of Action 52
RandD Progress 52
Englerin A - Drug Profile 53
Product Description 53
Mechanism of Action 53
RandD Progress 53
Growth Hormone Antagonists - Drug Profile 54
Product Description 54
Mechanism of Action 54
RandD Progress 54
Growth Disorders Therapeutics - Drug Profile Updates 55
Growth Disorders Therapeutics - Discontinued Products 60
Growth Disorders Therapeutics - Dormant Products 61
Growth Disorders - Product Development Milestones 62
Featured News and Press Releases 62
Apr 25, 2013: Ipsen Expects Increlex Supply Interruption Due To Supplier Manufacturing Issues 62
Mar 05, 2013: Prolor Biotech Receives Notice Of Allowance For New US Patent Covering Methods For Decreasing Body Fat With hGH-CTP 62
Sep 10, 2012: Ipsen Pharma Maintains Increlex Supply In US 62
Jun 07, 2012: Critical Pharma To Present Phase I Clinical Results Of CP024 At Endocrinology Society Annual Meeting 63
Nov 25, 2011: Hanmi Pharma Files With EMA For Orphan Drug Designation Of LAPS-rhGH 63
Nov 11, 2011: Hanmi Pharma To Maximize Commercial Opportunities Of LAPS-hGH Through EMA's Orphan Drug Designation And Pediatric Investigation Plan 63
Oct 27, 2011: Hanmi Pharma To Begin Phase II Study Of LAPS-hGH In European Territories 64
Oct 24, 2011: HanAll BioPharma Initiates Phase I Trial Of Vitatropin 64
Sep 27, 2011: Biopartners And LG Life Sciences Present Positive Phase III, 24 Months Efficacy And Safety Data For LB03002 Given To Children With Growth Hormone Deficiency 64
Aug 02, 2011: Swedish Orphan Biovitrum Announces First Patient Enrollment In Kiobrina Phase III Study 65
Appendix 66
Methodology 66
Coverage 66
Secondary Research 66
Primary Research 66
Expert Panel Validation 66
Contact Us 67
Disclaimer 67



List of Tables

Number of Products Under Development for Growth Disorders, H2 2013 9
Products under Development for Growth Disorders - Comparative Analysis, H2 2013 10
Number of Products under Development by Companies, H2 2013 12
Number of Products under Investigation by Universities/Institutes, H2 2013 13
Comparative Analysis by Late Stage Development, H2 2013 14
Comparative Analysis by Mid Clinical Stage Development, H2 2013 15
Comparative Analysis by Early Clinical Stage Development, H2 2013 16
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2013 17
Products under Development by Companies, H2 2013 18
Products under Investigation by Universities/Institutes, H2 2013 19
Novo Nordisk A/S, H2 2013 20
Ipsen S.A., H2 2013 21
Dong-A Pharmaceutical Co., Ltd., H2 2013 22
Zosano Pharma, Inc., H2 2013 23
PROLOR Biotech, Inc., H2 2013 24
Biovitrum AB, H2 2013 25
JCR Pharmaceuticals Co., Ltd., H2 2013 26
Myungmoon pharmaceutical Co.,Ltd., H2 2013 27
Asterion Ltd, H2 2013 28
GeneScience Pharmaceuticals Co., Ltd., H2 2013 29
Phage Biotechnology Corporation, H2 2013 30
USV Limited., H2 2013 31
Assessment by Monotherapy Products, H2 2013 32
Assessment by Stage and Route of Administration, H2 2013 34
Assessment by Stage and Molecule Type, H2 2013 36
Growth Disorders Therapeutics - Drug Profile Updates 55
Growth Disorders Therapeutics - Discontinued Products 60
Growth Disorders Therapeutics - Dormant Products 61



List of Figures

Number of Products under Development for Growth Disorders, H2 2013 9
Products under Development for Growth Disorders - Comparative Analysis, H2 2013 10
Products under Development by Companies, H2 2013 11
Products under Investigation by Universities/Institutes, H2 2013 13
Late Stage Products, H2 2013 14
Mid Clinical Stage Products, H2 2013 15
Early Clinical Stage Products, H2 2013 16
Discovery and Pre-Clinical Stage Products, H2 2013 17
Assessment by Monotherapy Products, H2 2013 32
Assessment by Route of Administration, H2 2013 33
Assessment by Stage and Route of Administration, H2 2013 34
Assessment by Molecule Type, H2 2013 35
Assessment by Stage and Molecule Type, H2 2013 36



Companies Mentioned

Novo Nordisk A/S
Ipsen S.A.
Dong-A Pharmaceutical Co., Ltd.
Zosano Pharma, Inc.
PROLOR Biotech, Inc.
Biovitrum AB
JCR Pharmaceuticals Co., Ltd.
Myungmoon pharmaceutical Co.,Ltd.
Asterion Ltd
GeneScience Pharmaceuticals Co., Ltd.
Phage Biotechnology Corporation
USV Limited.

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
2016 Immunodiagnostic Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Special Chemistry, Drug of Abuse, Endocrine Function, Immunoprotein, Therapeutic Drug Monitoring, and Tumor Marker Tests,  Opport

2016 Immunodiagnostic Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Special Chemistry, Drug of Abuse, Endocrine Function, Immunoprotein, Therapeutic Drug Monitoring, and Tumor Marker Tests, Opport

  • $ 47500
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-company survey from VPGMarketResearch.com contains 1,650 pages and 890 tables. The report provides a granular strategic analysis of over 100 clinical chemistry, TDM, endocrine, cancer, immunoprotein ...

2016 Tumor Markers in 32 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Test--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Emerging Technologies, Opportunities for Suppliers

2016 Tumor Markers in 32 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Test--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Emerging Technologies, Opportunities for Suppliers

  • $ 47400
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-country survey from VPGMarketResearch.com contains over 1,300 pages and 500 tables. The survey is designed to assist diagnostics industry executives, as well as companies planning to diversify ...

2016 Cancer Diagnostic Testing Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Tumor Marker--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Technology Trends

2016 Cancer Diagnostic Testing Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Tumor Marker--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Technology Trends

  • $ 47400
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-country survey from VPGMarketResearch.com contains over 1,300 pages and 500 tables. The survey is designed to assist diagnostics industry executives, as well as companies planning to diversify ...


Download Unlimited Documents from Trusted Public Sources

Therapy and Hormone Market in South Korea

  • December 2016
    4 pages
  • Therapy  

    Hormone  

    Cancer  

  • South Korea  

View report >

Opioid Market in the US

  • December 2016
    14 pages
  • Opioid  

  • United States  

View report >

Therapy Market in Denmark - Forecast

  • December 2016
    12 pages
  • Therapy  

  • Denmark  

View report >

ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.